Month: July 2025

Kverva, 3 July 2025: The Financial Supervisory Authority of Norway has on 2 July 2025 approved the prospectus prepared by SalMar ASA (the Company) in connection with the listing on the Oslo Stock Exchange of the Company’s two bond issues: (i) NOK 3,250,000,000 senior unsecured green bonds issued 25 January 2025, with maturity 30 January 2030 (with ISIN NO0013467316); and (ii) NOK 1,100,000,000 senior unsecured green bonds issued 25 January 2025, with maturity 30 January 2032 (with ISIN NO0013467324). The prospectus with appendices is available on the Company’s website www.salmar.no. For further information, please contact: Håkon Husby, Head of Investor Relations hakon.husby@salmar.no, +47 936 30 449 This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate. Organon has announced results from the Phase 2 ELENA proof-of-concept, where the drug candidate OG-6219 was evaluated in patients with endometriosis-related pain. The outcomes of the study failed to demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to placebo. Based on the results, Organon plans to discontinue the clinical development program with OG-6219. As part of the 2021 acquisition, Organon acquired Forendo...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx was evaluated in combination with a 26-week steroid taper and compared to placebo plus a 52-week steroid taper. Cosentyx did not demonstrate a statistically significant improvement in sustained remission at Week 52 compared to placebo. While the secondary outcomes did not show statistical superiority, Cosentyx showed numerically better outcomes compared to placebo for cumulative steroid...

Q3 Fiscal 2025 Revenues Issy-les-Moulineaux, France – July 3rd, 2025 Pluxee delivers solid organic growth performance in Q3 Fiscal 2025, in line with full-year objectives HighlightsRobust commercial and topline performance, supported by balanced and resilient business model fueled by multiple growth drivers, maintaining the Group on track to achieve full-year targets 310 million euros Total Revenues in Q3 Fiscal 2025, growing organically by +11.1%, driven by Employee Benefits, up +12.3% organically 270 million euros Operating revenue, up +11.1% organically, more weighted toward Latin America and Rest of the world in line with anticipations 39 million euros Float revenue, growing up +10.8% organically at a slightly stronger pace than expected Continuous execution of M&A strategy, with the signing of the acquisition of MyBenefits...

VANCOUVER, British Columbia, July 03, 2025 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (“CLC” or the “Company“) (CSE: CLC) announced today that it will not be filing its annual financial statements, accompanying management’s discussion and analysis and related chief executive officer (“CEO“) and chief financial officer (“CFO“) certifications for the financial year ended February 28, 2025 (collectively, the “Annual Filings“), within the period prescribed for the filing of such documents under Parts 4, 5 and 6 of National Instrument 51-102 Continuous Disclosure Obligations and pursuant to National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, namely within 120 days of year-end, being June 30, 2025 (the “Filing...

VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB: DMGGF) (FRANKFURT: 6AX) (“DMG” or the “Company”), a vertically integrated blockchain and data center technology company, today announces its preliminary operational results for June 2025:Bitcoin mined: 23 BTC (vs 31 BTC in May 2025) Hashrate: 1.56 EH/s (vs 1.89 EH/s in May 2025) Bitcoin balance: 341 BTC (vs 350 BTC in May 2025)During June 2025, DMG’s realized hashrate was 1.56 EH/s, down 18% from the 1.89 EH/s reported in May, as the Company experienced an unscheduled electrical outage of nearly two days at its Christina Lake facility and faced continued challenges operating its hydro infrastructure. In particular, a regional lightning storm resulted in the tripping of a main substation breaker...

New awards programme highlights exceptional credit cards, digital banks, investments and insurances to help Singaporeans make smarter financial choices SINGAPORE, July 03, 2025 (GLOBE NEWSWIRE) — MoneyHero Limited (NASDAQ: MNY) (“MoneyHero” or the “Company”), a leading personal finance aggregation and comparison platform, as well as a digital insurance brokerage provider in Greater Southeast Asia, today announced the launch of “SingSaver Best-Of Awards”, an annual awards programme recognising Singapore’s most outstanding personal finance products. The new awards programme will spotlight 45 exceptional personal finance products across categories including credit cards, digital banks, investing, and insurance. Each product will be rigorously evaluated by the MoneyHero Group team, alongside an esteemed panel of prominent local personal...